Agios Pharmaceuticals AGIO Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $66.05M+22.2% | $54.03M+20.6% | $44.79M+9.6% | $40.88M+10.4% | $37.04M+1.5% | ||
| $6.58M+3.7% | $6.35M+10.8% | $5.73M+18.6% | $4.83M+4.5% | $4.62M+11.0% | ||
| $59.47M+24.7% | $47.68M+22.1% | $39.07M+8.4% | $36.05M+11.2% | $32.41M+0.2% | ||
| 90%+1.8pp | 88.3%+1.0pp | 87.2%-1.0pp | 88.2%+0.7pp | 87.5%-1.1pp | ||
| $347.94M+2.5% | $339.54M+1.6% | $334.29M+4.5% | $319.95M+4.8% | $305.41M+1.4% | ||
| $187.06M+3.8% | $180.28M0.0% | $180.37M+1.5% | $177.63M+6.2% | $167.3M+6.7% | ||
| $541.58M+2.9% | $526.16M+1.1% | $520.38M+3.6% | $502.41M+5.3% | $477.33M+3.3% | ||
| -$475.53M-0.7% | -$472.13M+0.7% | -$475.59M-3.0% | -$461.53M-4.8% | -$440.29M-3.4% | ||
| -720%+154pp | -873.9%+188pp | -1,061.8%+67.3pp | -1,129.1%+59.7pp | -1,188.9%-22.4pp | ||
| $51.09M-9.4% | $56.38M-9.0% | $61.98M+0.5% | $61.67M+11.6% | $55.28M+15.0% | ||
| $822K-58.0% | $1.96M-43.6% | $3.47M-31.4% | $5.05M-17.3% | $6.11M-5.9% | ||
| -$422.6M-2.4% | -$412.78M— | —— | —— | —— | ||
| -639.8%+124pp | -764%— | —— | —— | —— | ||
| -$7.25-2.0% | -$7.11— | —— | —— | —— | ||
| -$470.27M-0.7% | -$466.96M+0.7% | -$470.31M-3.1% | -$456.28M-5.0% | -$434.71M-3.5% | ||
| -712%+152pp | -864.3%+186pp | -1,050%+66.3pp | -1,116.3%+57.5pp | -1,173.8%-22.8pp | ||
| -$475.53M-0.7% | -$472.13M+0.7% | -$475.59M-3.0% | -$461.53M-4.8% | -$440.29M-3.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Agios Pharmaceuticals's profit margins?
- Gross margin is 90.0% and operating margin is -720.0%, with a -639.8% net margin.
- Where does Agios Pharmaceuticals's income statement data come from?
- Every line is extracted from Agios Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.